絞り込み

16555

広告

Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes.

著者 Chao CT , Wang J , Wu HY , Chien KL , Hung KY
Oncotarget.2017 Aug 08 ; 8(32):53028-53040.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (79view , 0users)

Full Text Sources

Dipeptidyl peptidase 4 inhibitor (DPP4i) use potentially slows the progression of diabetic kidney disease, but its effects on the risk of acute kidney injury (AKI) are unclear. We aimed to assess the association between DPP4i use and incident AKI episodes from a nationally representative cohort in Taiwan.
PMID: 28881791 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード